EllenRx®Oncology

Keytruda denied by insurance? How to appeal

pembrolizumab · Sources below

Used for
21 conditions (see above)
How it's given
IV infusion
Prior authorization usually required?
Varies by plan

Why was Keytruda denied, and what can I do?

  1. Decode your denial letter: Ellen explains the reason in plain words.
  2. Check your denial type and your rights (Medicare or Medicaid if that's your coverage).
  3. Build your appeal, with the step-by-step appeal guide.
Decode my Keytruda denial

How can I lower the cost of Keytruda?

If you have Medicare or Medicaid, check each program's terms before you apply.

Safety information

From FDA-approved prescribing information for Keytruda (PD-1 Inhibitor (Immune Checkpoint)).

Do not use if

  • Clinically significant hypersensitivity to pembrolizumab

Key warnings

  • Immune-mediated adverse events in any organ system, pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, skin reactions
  • Monitor thyroid function, liver enzymes, renal function at baseline and periodically
  • May require high-dose corticosteroids for immune-mediated toxicity
  • Withhold or permanently discontinue based on severity of immune-mediated reactions

This is not a complete list. See the full Keytruda prescribing information or ask your pharmacist for complete safety information.

Questions about Keytruda coverage

Why was Keytruda denied for my cancer?

The most common reason is missing biomarker documentation. Keytruda requires PD-L1 testing (using the Dako 22C3 companion diagnostic) or MSI-H/dMMR status for most indications. Without these test results submitted with the PA, denial is almost automatic.

Is Keytruda covered by insurance?

Keytruda is covered by most plans for FDA-approved indications with proper documentation. As a Protected Class drug (oncology), insurers face legal restrictions on denying cancer therapies, but they can and do deny for missing documentation.

How do I expedite a Keytruda appeal?

Use the words 'Rapid Disease Progression' and 'Clinical Urgency: Life-Threatening Malignancy' when requesting expedited review. Your oncologist should request a peer-to-peer call and cite the NCCN Category 1 recommendation for your specific tumor type.

Can my oncologist do a peer-to-peer for Keytruda?

Yes, and they should. Peer-to-peer reviews for oncology drugs have a high overturn rate. Have your oncologist cite KEYNOTE trial data specific to your cancer type and reference the NCCN Compendium listing.

Sources: FDA prescribing information for Keytruda (DailyMed) and public payer policy examples.

Not medical advice. This page is for educational and informational purposes only. It does not replace professional medical judgment. Always consult your prescribing physician or pharmacist before starting, stopping, or changing any medication. Ellen does not provide medical advice, diagnose conditions, or recommend treatments. Coverage rules vary by plan and change often; confirm with your plan's current policy.